223 related articles for article (PubMed ID: 19474376)
1. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
Schor-Bardach R; Alsop DC; Pedrosa I; Solazzo SA; Wang X; Marquis RP; Atkins MB; Regan M; Signoretti S; Lenkinski RE; Goldberg SN
Radiology; 2009 Jun; 251(3):731-42. PubMed ID: 19474376
[TBL] [Abstract][Full Text] [Related]
2. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
[TBL] [Abstract][Full Text] [Related]
3. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
Hakimé A; Hines-Peralta A; Peddi H; Atkins MB; Sukhatme VP; Signoretti S; Regan M; Goldberg SN
Radiology; 2007 Aug; 244(2):464-70. PubMed ID: 17641366
[TBL] [Abstract][Full Text] [Related]
4. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
Zhang L; Bhasin M; Schor-Bardach R; Wang X; Collins MP; Panka D; Putheti P; Signoretti S; Alsop DC; Libermann T; Atkins MB; Mier JW; Goldberg SN; Bhatt RS
PLoS One; 2011 Apr; 6(4):e19144. PubMed ID: 21559452
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Yuen JS; Sim MY; Siml HG; Chong TW; Lau WK; Cheng CW; Huynh H
Br J Cancer; 2011 Mar; 104(6):941-7. PubMed ID: 21407223
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Murakami M; Zhao S; Zhao Y; Chowdhury NF; Yu W; Nishijima K; Takiguchi M; Tamaki N; Kuge Y
Int J Oncol; 2012 Nov; 41(5):1593-600. PubMed ID: 22965141
[TBL] [Abstract][Full Text] [Related]
7. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
Sabir A; Schor-Bardach R; Wilcox CJ; Rahmanuddin S; Atkins MB; Kruskal JB; Signoretti S; Raptopoulos VD; Goldberg SN
AJR Am J Roentgenol; 2008 Jul; 191(1):133-9. PubMed ID: 18562736
[TBL] [Abstract][Full Text] [Related]
8. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Kang HC; Tan KS; Keefe SM; Heitjan DF; Siegelman ES; Flaherty KT; O'Dwyer PJ; Rosen MA
AJR Am J Roentgenol; 2013 Jan; 200(1):120-6. PubMed ID: 23255750
[TBL] [Abstract][Full Text] [Related]
9. Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
De Bazelaire C; Rofsky NM; Duhamel G; Michaelson MD; George D; Alsop DC
Acad Radiol; 2005 Mar; 12(3):347-57. PubMed ID: 15766695
[TBL] [Abstract][Full Text] [Related]
10. Arterial spin-labeling MR imaging of renal masses: correlation with histopathologic findings.
Lanzman RS; Robson PM; Sun MR; Patel AD; Mentore K; Wagner AA; Genega EM; Rofsky NM; Alsop DC; Pedrosa I
Radiology; 2012 Dec; 265(3):799-808. PubMed ID: 23047841
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Hahn OM; Yang C; Medved M; Karczmar G; Kistner E; Karrison T; Manchen E; Mitchell M; Ratain MJ; Stadler WM
J Clin Oncol; 2008 Oct; 26(28):4572-8. PubMed ID: 18824708
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Flaherty KT; Rosen MA; Heitjan DF; Gallagher ML; Schwartz B; Schnall MD; O'Dwyer PJ
Cancer Biol Ther; 2008 Apr; 7(4):496-501. PubMed ID: 18219225
[TBL] [Abstract][Full Text] [Related]
14. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
Ranze O; Hofmann E; Distelrath A; Hoeffkes HG
Onkologie; 2007 Sep; 30(8-9):450-1. PubMed ID: 17848817
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
16. A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Richards TM; Plowman PN; Reznek R; Ball SA
Clin Oncol (R Coll Radiol); 2009 Oct; 21(8):633-4. PubMed ID: 19380217
[No Abstract] [Full Text] [Related]
17. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
18. Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Kususda Y; Miyake H; Gleave ME; Fujisawa M
Br J Cancer; 2012 Jun; 106(12):1945-52. PubMed ID: 22588555
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
[TBL] [Abstract][Full Text] [Related]
20. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]